profit from every $100 of sales.
$0$100
Innocan Pharma
$1.29+0.00% today
-91.0% in 1 year
1-year low $1.291-year high $14.26
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Innocan Pharma sold, what it kept, and what it did with the cash.
Sales went from $2.56 million in 2022 to $26.6 million in 2025, with -$1.12 million of profit last year.
SalesProfit
Innocan Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Innocan Pharma | No profit yet | ||
 Merck KGaA | 25.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Innocan Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisQuestions about Innocan Pharma
Is Innocan Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Innocan Pharma AI analysis
What does Innocan Pharma do?
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. It is in Drug Manufacturers - Specialty & Generic.
Does Innocan Pharma pay a dividend?
No. Innocan Pharma does not pay a dividend at the moment.
Is Innocan Pharma stock halal?
No. Innocan Pharma does not pass our halal screen: its cash and confirmed interest-bearing investments are 115% of its market value, at or above the 33% limit. How we check
How has Innocan Pharma stock done over the past year?
Down 91.0% over the past twelve months, to $1.29. It traded between $1.29 and $14.26 and is 91.0% below its high.
Who are Innocan Pharma's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Innocan Pharma's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.